Background. Diabetes guidelines recommend individualizing glycemic goals (A1C) for older patients. The aim of this study was to assess a personalized Web-based decision support tool. Methods. We randomized physicians and their patients with type 2 diabetes (65 years of age) to a support tool or educational pamphlet (75:25 patients). Prior to a visit, intervention patients interacted with the tool, which provided personalized risk predictions and elicited treatment preferences. Main outcomes included 1) patient-doctor communication, 2) decisional conflict, 3) changes in goals, and 4) intervention acceptability. Results. We did not find significant differences in proportions of patients who had an A1C discussion (91% intervention v. 76% control; P = 0.19). Intervention patients had larger declines in the informed subscale of decisional conflict (-20 v. 0, respectively; P = 0.04). There were no significant differences in proportions of patients with changes in goals (49% v. 28%, respectively; P = 0.08). Most intervention patients reported that the tool was easy to use (91%) and helped them to communicate (84%). A limitation was that this was a pilot trial at one academic institution. Conclusions. Web-based decision support tools may be a practical approach to facilitating the personalization of goals for chronic conditions. Trial registration: NCT02169999 (https://clinicaltrials.gov/show/NCT02169999). Key words: type 2 diabetes; aging; personalized medicine; decision aids; decision support; chronic disease modeling; randomized trial. (Med Decis Making 2017;37:611-617) O lder patients with diabetes are highly heterogeneous in terms of functional status, comorbidities, and life expectancy, and these differences may alter the risks and benefits of achieving diabetes care goals. In 2003, the American Geriatrics Society published one of the earliest diabetes care guidelines, encouraging providers to consider less intensive glucose control goals (A1C \8%) among frail, older patients with limited life expectancy (\5 years) while continuing to pursue intensive glucose control (A1C \7%) among relatively healthy older patients. 1 Despite the dissemination of this guideline, considerable evidence suggests that diabetes care is not individualized in clinical practice. [2] [3] [4] The lack of individualization may be due to the difficulty of implementing recommendations in busy practices. In a variety of clinical domains, decision support interventions have been found to improve guideline adherence. [5] [6] [7] We developed a personalized Webbased decision support tool (Personal DC) that combines the features of a traditional decision aid with quantitative risk prediction. To generate pilot data for a larger trial, we conducted a randomized trial of the tool in 2 outpatient clinics.
METHODS
This pilot randomized controlled trial took place in 2 clinics of the University of Chicago and was approved by the Institutional Review Board. All attending physicians were approached to enroll patients. We enrolled English-speaking patients aged 65 years, with type 2 diabetes, no dementia, and who had been seen in 2011. Randomization occurred at the physician level (3:1 intervention to control ratio). We enrolled 20 intervention and 7 control physicians and 75 intervention and 25 control patients (Appendix Figure A) . Physicians were not blinded to study objectives or allocation. Patients were blinded to study hypotheses and were unaware of allocation.
Intervention Protocol
At baseline, intervention physicians underwent 1 hour of in-person training on the principles of geriatric diabetes 1 and the use of the decision support tool. Intervention patients met with a research assistant 1 hour prior to their next scheduled clinic appointment. Patients were given brief instructions on the use of the tool and received minor assistance with the computer, if necessary. The Web site was presented via a touch-screen laptop for easy use if the patient had difficulty manipulating a mouse.
Main components of the decision support tool were 1) an interactive diabetes education module, 2) a simulation model for calculating life expectancy and risk of developing complications, 3) treatment preference elicitation, 4) geriatric condition screening, and 5) a personalized patient printout. Patient responses regarding demographics, biometrics, comorbidities, and functional status were fed into the model. The model integrates the United Kingdom Prospective Diabetes Study (UKPDS) simulation model of diabetes outcomes 8 and a geriatric mortality prediction model that accounts for functional status and comorbid illness. 9, 10 The model calculated life expectancy, lifetime risk of developing a heart attack (at A1C of 7%), and risk of amputation or blindness (at A1C of 7%, 8%, and 9%). Personalized risks, patient preferences, and geriatric screening results were summarized in the printout (Appendix Figure B ). Patients received 2 copies with instructions to give 1 copy to their doctor.
Control Protocol
Control physicians received no formal training. Control patients met with a research assistant 1 hour prior to their scheduled appointment and were given an educational brochure regarding the A1C test. 11
Outcomes and Follow-up
Sources of data included 1) patient surveys, 2) physician surveys, and 3) electronic medical records. In the patient presurveys and postsurveys, we asked patients questions about their 1) knowledge about the A1C test, 2) decisional conflict related to diabetes management, 12, 13 3) preferences regarding participation in treatment decisions and relationship with their physician, 14 4) diabetes and nondiabetes health status questions, 15, 16 and 5) current self-management of diabetes. 17 In separate physician presurveys and postsurveys regarding their individual patients, physicians were asked to estimate life expectancy and identify frailty status, A1C goals, patient's knowledge of his or her A1C goal, geriatric syndromes, and patient's preferences. Electronic medical records were abstracted for comorbidities, diabetes-related complications, medications, and current risk factor levels. The primary outcomes for this study were 1) patient and physician communication about A1C goals, 2) patient decisional conflict, 3) changes in identified goals, and 4) feasibility of the intervention.
Statistical Analysis
The targeted sample size (75:25) for the pilot trial was based on the assumption that we would have 80% power to detect a 29% difference (49% intervention and 20% control) in the proportion of patients with guideline-adherent goals. Each survey outcome was analyzed with a generalized linear mixed-effects model. All models included random effects for physicians and patients to account for the clustering of patients within a physician and for within-subject correlations between pre-and posttime points. An interaction term between the intervention effect and survey time point evaluated the intervention effect on outcomes over time. In sensitivity analyses, we conducted McNemar tests and 2sample t tests to compare the preintervention and postintervention outcomes within each study arm. P values of \0.05 were considered statistically significant. All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC).
RESULTS
Patients in each trial arm were similar in sex, race/ethnicity, age, duration of diabetes, and glycemic control ( Table 1 ). The control group had a significantly larger proportion of patients exclusively using insulin (32%) compared to the intervention group (11%) (P = 0.02). The control group had a significantly higher proportion of patients with reports of hypoglycemia in the last month (56% v. 28%, respectively; P = 0.02). The rates of other conditions were similar.
Patient and Physician Communication about A1C Goals
Intervention patients (77% v. 64%, respectively; P = 0.24) and their physicians (91% v. 76%, respectively; P = 0.19) did not report significantly different rates of A1C discussions compared to control patients (Table 2) . Additionally, the proportion of intervention patients with a physician reporting patient knowledge of their A1C goal rose from 32% to 81%, but this was not significantly different from the experience of the control group (52% to 60%) (P = 0.09).
Decisional Conflict
Decisional conflict scores regarding A1C goal selection declined for both intervention and control patients, but the decline was not significantly different ( Table 3 ). The overall decisional conflict score declined from 52.7 to 24.5 for intervention patients compared to 51.2 to 36.6 for control patients (P = 0.07). Among subscale scores, the largest differences were for the informed subscale score, where intervention patients had a significant decline from 60.9 to 40.9, while control patients' scores remained unchanged from preresults to postresults (P = 0.04).
Changes in Physician-Identified Goals
Nearly half of the intervention patients (49%) had their physician report a change in the A1C goal following the intervention in comparison to 28% of control patients; this was not statistically different (P = 0.08) ( Table 4 ). More detailed analyses of specific patient subgroups (e.g., life expectancy groups) and goal selection did not reveal statistically significant differences between the intervention and control groups (Appendix Table A ).
Feasibility
Most intervention patients reported that the Web site was easy to use and understand (91%) and that the site helped them to talk with their doctor about their diabetes care (84%). The average time on the site was 7 minutes. Most physicians reported that the experience utilizing the decision aid with the patient was acceptable (53%).
DISCUSSION
Multiple clinical guidelines are encouraging the active personalization of diabetes care goals. [18] [19] [20] [21] [22] Our Web-based decision support intervention differs from the interventions of prior studies because we focus on 1) glucose goal setting, 2) geriatric populations, and 3) personalization of risk estimates. Previous diabetes decision aids have focused on therapeutic decisions such as statin use and choice of glucose-lowering drugs and have enhanced decision making and sometimes improved medication adherence. [23] [24] [25] [26] [27] [28] Our decision support tool significantly reduced patients' informed subscale of decisional conflict scores. Other findings were not statistically significant but promising. Based on point estimates, intervention patients had more communication about A1C goals during clinic visits, more awareness of their personal A1C goal, and more changes in goal selection by their physicians. The intervention was also acceptable to patients and required very little time prior to visits.
Our study has limitations. Our simulation model was based on the original UKPDS model. 8 We used this model because of its widespread use, public availability, and prior external validation. 29 Future versions of this intervention will need to incorporate updates to the UKPDS model and more recent clinical trial findings. 30, 31 Our pilot study was underpowered and was primarily designed to address feasibility issues and to gather data in preparation for a larger trial. Due to resource limitations, the study design was purposely imbalanced to maximize experience with the intervention. By chance, our control patients were more likely to be insulin users and had higher rates of hypoglycemia. Our trial also took place at the clinics of a single urban academic institution, and findings may differ in other settings. Our data collection did not include direct observations of clinical encounters, which would have helped us to understand intervention effects on the quality of discussions.
Despite its limitations, our study indicates that Web-based personalized decision support can be feasibly introduced into clinical practice. A much larger clinical trial is needed to determine how the longitudinal use of decision support influences goal selection and treatments over time and if structured personalization in diabetes care will influence health outcomes such as hypoglycemia and quality of life. Note: Values reported are the percentage of patients, unless otherwise indicated. a. All reported P values are from generalized linear mixed models that account for clustering by the physician. b. A change in goal was defined as a 0.5% increase or decrease from presurvey to postsurvey responses. When a range was specified, the upper A1c goal was used to assess change. c. Model-predicted life expectancy was taken from the life expectancy predicted by the embedded prediction model in the Personal DC tool. Control patients were also run through the model to generate modelpredicted life expectancy for a comparison of results.
